Jude Masannat

6PUBLICATIONS
29CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 29, 2025
Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study.

Samantha I Liang, Zoe Quandt, Sara Wienke

|Mar 28, 2022
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

Christine H Chung, Jiannong Li, Conor E Steuer

|Apr 03, 2021
Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study.

Christine H Chung, Marcelo Bonomi, Conor E Steuer

|Dec 19, 2019
Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.

Janis V de la Iglesia, Robbert J C Slebos, Laura Martin-Gomez

|Mar 22, 2018
βArrestin2 Mediates Renal Cell Carcinoma Tumor Growth.

Jude Masannat, Hamsa Thayele Purayil, Yushan Zhang

Pageof 1

Frequent Collaborators

2 joint publications

J Trad Wadsworth

1 joint publications

Daiqing Liao

1 joint publications

Jamie K Teer

1 joint publications

Garrick Aden-Buie